It may not be all lost for 2023 warrants (RVX-WT-A) if we go with the February 4th, 2021 Market Update slide #8.
TARGETED -GLOBAL DEVELOPMENT PLAN
-(2021) Patient enrollment will start H2 2021. (pending COVID-19 issues)
-(2021) Targeted enrollment should be completed 4 months from start
-(2022) Interim analysis of 300 targeted patient events should happen 6 months after enrollment
-(2023 / 2 years) Pending interim success FDA approval is possible due to the Breakthrough Therapy Designation
Koo
